Image credit: Shutterstock / T Schneider. Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis B. The company reported ...

The investigational combo of Vir’s monoclonal antibody tobevibart and Alnylam-discovered siRNA elebsiran was measured in a phase 2 trial for patients with chronic hepatitis B (CHB). Participants ...

The biotech is collaborating with pharma giant Gilead Sciences, which will have the right to opt in to further development and commercialization of the drug following the phase 1b study. Late last ...

Novotech is the global leader in Hepatitis B research, having supported 90 Hepatitis B trials and counting, initiating 340+ sites and enrolling 5,000+ participants across all trial phases, including ...

Objective High serum HBV DNA levels are associated with high risks of hepatocellular carcinoma (HCC) and cirrhosis in patients with chronic hepatitis B (CHB). Although the immune-tolerant (IT) phase ...

The hepatitis B surface antibody test (HBsAb) detects proteins that are made by the immune system (antibodies) in response to the hepatitis B virus (HBV). The test is used to find out if you are ...

Diagnosis of HBV infection requires serological testing for HBsAg and for acute infection additional testing for IgM hepatitis B core antibody (IgM anti-HBc, for the window period when neither HBsAg ...

28, 2025 (GLOBE NEWSWIRE) -- The "Hepatitis B Therapeutics: Competitive Landscape ... with one asset in the pre-registration stage, one asset in Phase III development, and 36 assets in Phase ...

Patients with CHB in the indeterminate phase have incidence rates of hepatic decompensation, cirrhosis, and liver cancer. Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of ...

Hepatitis B is a vaccine-preventable viral disease that involves inflammation of the liver. The hepatitis B virus (HBV) usually leads to a short-term infection known as acute hepatitis B. If their ...

Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability ...